Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for ImmunityBio (IBRX) over the last 12 years, with Q3 2025 value amounting to $173.5 million.

  • ImmunityBio's Cash from Financing Activities rose 101358.62% to $173.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $452.3 million, marking a year-over-year increase of 2052.98%. This contributed to the annual value of $281.6 million for FY2024, which is 4955.95% down from last year.
  • As of Q3 2025, ImmunityBio's Cash from Financing Activities stood at $173.5 million, which was up 101358.62% from $172.8 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Cash from Financing Activities peaked at $326.0 million during Q4 2021, and registered a low of -$982000.0 during Q1 2025.
  • For the 5-year period, ImmunityBio's Cash from Financing Activities averaged around $101.3 million, with its median value being $98.3 million (2021).
  • As far as peak fluctuations go, ImmunityBio's Cash from Financing Activities skyrocketed by 28951333.33% in 2023, and later plummeted by 10960.39% in 2025.
  • Over the past 5 years, ImmunityBio's Cash from Financing Activities (Quarter) stood at $326.0 million in 2021, then tumbled by 66.27% to $109.9 million in 2022, then skyrocketed by 82.41% to $200.5 million in 2023, then tumbled by 46.68% to $106.9 million in 2024, then surged by 62.27% to $173.5 million in 2025.
  • Its last three reported values are $173.5 million in Q3 2025, $172.8 million for Q2 2025, and -$982000.0 during Q1 2025.